Peak-Muscle.com  

Welcome to the Peak-Muscle.com forums.

You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. Come join us in on one of the best online fitness communities. We have 16,000 members that are likeminded towards a fitness, bodybuilding lifestyle. Registration is free and only takes but a few minutes. By joining our free community you will have access to communicate privately with other members (PM), respond to polls, upload content and access many other special features. You will be able to create threads to discuss and or create a fitness regimen. Or just bounce ideas off of some very knowledgeable members. So don't miss out. Registration is fast, simple and absolutely free so please, join our community today!

Register FAQ Members List Calendar Arcade Mark Forums Read
Go Back   Peak-Muscle.com > Bodybuilding and Fitness Discussion > Diet and Nutrition
User Name
Password

Reply
 
Thread Tools Display Modes
Old 03-23-2022, 11:57 AM   #1
liftsiron
Administrator
 
liftsiron's Avatar
 

Join Date: Nov 2003
Location: Cimmeria
Posts: 18,388
liftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant future
Semaglutide weight loss drug

Semaglutide
From Wikipedia, the free encyclopedia





Semaglutide, sold under the brand name Ozempic among others, is an antidiabetic medication used for the treatment of type 2 diabetes and long-term weight management.[15][16][17]

Semaglutide acts like human glucagon-like peptide-1 (GLP-1) in that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, so a once-a-week injection is sufficient.[18]

An injectable version (Ozempic) was approved for medical use in the United States in December 2017,[19] and in the European Union,[12] Canada,[20] and Japan in 2018. A version which is taken by mouth (********) was approved for medical use in the United States in September 2019,[21] and in the European Union in April 2020.[13] It is the first glucagon-like peptide receptor protein treatment approved for use in the United States that does not need to be injected.[22] It was developed by Novo Nordisk. Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.[9]

In June 2021, the US Food and Drug Administration (FDA) approved semaglutide injection sold under the brand name Wegovy for long-term weight management in adults.[11][17]
Contents



Medical uses

Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[9][10]

Semaglutide (Wegovy) is also indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) ≥ 30 kg/m2) or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.[11][14][17]
Adverse effects

Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.[9] In people with heart problems, it can cause damage to the retina of the eye (retinopathy).[23] Other, less common side effects include kidney problems, allergic reactions, low blood sugar, and pancreatitis.[22]
Contraindications

It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2.[10][9]
Mechanism of action

Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level.[24] It also appears to enhance growth of β cells in the pancreas, which are the sites of insulin production.[25] It also inhibits glucagon, which is a hormone that increases blood sugar. It additionally reduces food intake by lowering appetite and slows down digestion in the stomach.[23] In this way it reduces body fat.[26]
Structure

Semaglutide is chemically similar to human glucagon-like peptide-1 (GLP-1), with 94% similarity. The only differences are two amino-acid substitutions at positions 8 and 34, where alanine and lysine are replaced by 2-aminoisobutyric acid and arginine, respectively.[27] Amino-acid substitution at position 8 prevents chemical breakdown by dipeptidyl peptidase-4. In addition, lysine at position 26 is in its derivative form (acylated with stearic diacid). Acylation with a spacer and C-18 fatty diacid chain increases the drug binding to blood protein (albumin), which enables longer presence in the blood circulation.[28] Its half-life in the blood is about 7 days (165–184 hours); therefore, once-weekly injection is enough.[18][25]
History

Semaglutide was developed in 2012,[29] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[30] It was given the brand name Ozempic. Clinical trials were started in 2015, and phase III was completed in 2016.[31][full citation needed]

Researchers at the University of Leeds and Novo Nordisk reported in 2017, that it can also be used for the treatment of obesity.[32] It reduces hunger, food craving and body fat.[33] A Phase 3 Randomized Controlled Trial found that once-weekly injection of 2.4 mg of the drug resulted in an average change of −14.9% body weight at 68 weeks compared to −2.4% for the placebo.[34]

The US FDA New Drug Application (NDA) was filed in December 2016, and in October 2017, the FDA Advisory Committee voted 16–0 in favor.[35] Approval was announced in December 2017.[19] It can be used as both injection-type or oral-type drug.[36] The marketing authorization in the European Union was granted in February 2018.[12][37] The Japanese Ministry of Health, Labour and Welfare announced approval on 23 March 2018.[38] Health Canada issued approval on 4 January 2018.[20]

Semaglutide was approved for medical use in Australia in August 2019 for "the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; and as monotherapy when metformin is not tolerated or contraindicated."[1][3]
__________________
ADMIN/OWNER@Peak-Muscle
liftsiron is online now   Reply With Quote
Old 03-27-2022, 06:29 PM   #2
Kluso
Vet
 
Kluso's Avatar
 

Join Date: Dec 2016
Location: East Coast
Age: 49
Posts: 869
Kluso has a spectacular aura aboutKluso has a spectacular aura aboutKluso has a spectacular aura about
Interesting!
Kluso is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -5. The time now is 05:56 AM.


Powered by: vBulletin Version 3.8.11
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.